Cargando…

Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study

BACKGROUND: Response to disease modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) is often heterogeneous. We aimed to identify types of disease activity trajectories following the initiation of a new biologic DMARD (bDMARD). METHODS: Pooled analysis of nine national registries of p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Courvoisier, D.S., Alpizar-Rodriguez, D., Gottenberg, J.E., Hernandez, M.V., Iannone, F., Lie, E., Santos, M.J., Pavelka, K., Turesson, C., Mariette, X., Choquette, D., Hetland, M.L., Finckh, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049989/ https://www.ncbi.nlm.nih.gov/pubmed/27558858 http://dx.doi.org/10.1016/j.ebiom.2016.08.024

Ejemplares similares

The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries
por: Finckh, A, et al.
Publicado: (2015)

Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?
por: Mongin, Denis, et al.
Publicado: (2019)

Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries
por: Dominique, Alyssa, et al.
Publicado: (2023)

The Role of Nutritional Factors and Intestinal Microbiota in Rheumatoid Arthritis Development
por: Alpízar-Rodríguez, Deshiré, et al.
Publicado: (2020)

Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers
por: Mercer, Louise K, et al.
Publicado: (2017)

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study
por: Emery, P, et al.
Publicado: (2015)

Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire
por: Haraoui, Boulos, et al.
Publicado: (2011)

Ultrasound is not associated with the presence of systemic autoimmunity or symptoms in individuals at risk for rheumatoid arthritis
por: Brulhart, Laure, et al.
Publicado: (2019)

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
por: Lauper, Kim, et al.
Publicado: (2022)

Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis
por: Jarlborg, Matthias, et al.
Publicado: (2020)

ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome?
por: Payet, J, et al.
Publicado: (2015)

Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project
por: Mercer, Louise K, et al.
Publicado: (2017)

Measuring ACPA in the general population or primary care: is it useful?
por: Finckh, Axel, et al.
Publicado: (2020)

Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis
por: Rivière, Elodie, et al.
Publicado: (2018)

Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2009)

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2011)

Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study
por: Lane, Jennifer C E, et al.
Publicado: (2020)

Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional study
por: Wells, Philippa M, et al.
Publicado: (2020)

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
por: Finckh, A, et al.
Publicado: (2010)

Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study
por: Lane, Jennifer C E, et al.
Publicado: (2020)

Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
por: Diamantopoulos, Alex, et al.
Publicado: (2014)

Editorial: The interplay between the oral Microbiota and rheumatoid arthritis
por: Manoil, Daniel, et al.
Publicado: (2022)

Autoantibodies in Rheumatoid Arthritis – Laboratory and Clinical Perspectives
por: Rönnelid, Johan, et al.
Publicado: (2021)

Multinational democracies /
Publicado: (2001)

Multinational corporations
Publicado: (1990)

The multinational corporation
por: Liebenau, Jonathan
Publicado: (1984)

Multinational Telecommunications
por: Collective
Publicado: (1977)

Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritis
por: Gilbert, Benoit Thomas P, et al.
Publicado: (2021)

Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation study
por: Mongin, Denis, et al.
Publicado: (2022)

A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]
por: Collantes, Eduardo, et al.
Publicado: (2002)

Exposure of community pharmacists to COVID-19: A multinational cross-sectional study
por: Khojah, Hani M.J., et al.
Publicado: (2021)

Money in the multinational enterprise : a study of financial policy /
por: Robbins, Sidney M.
Publicado: (1974)

Managing the multinational enterprise : organization of the firm and ownership of the subsidiaries /
por: Stopford, John M.
Publicado: (1972)

Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients
por: Burkard, Theresa, et al.
Publicado: (2021)

The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study
por: Moots, Robert J., et al.
Publicado: (2017)

A systematic review of infliximab in the treatment of early rheumatoid arthritis
por: Du Pan, Sophie Martin, et al.
Publicado: (2007)

Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study
por: Moots, Robert J., et al.
Publicado: (2017)

Multinational business finance /
por: Eiteman, David K.
Publicado: (2001)

Multinational business finance /
por: Eiteman, David K.
Publicado: (1998)

Multinational business finance /
por: Eiteman, David K.
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_qofl3mvfu09oe666rdaa67h944